[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fibrosis-lung\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fibrosis-lung":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,68,94],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100588363","phase-2-development-of-fapi-pet-as-a-non-invasive-biomarker-of-pulmonary-fibrogenesis-100588363",false,"NCT06940427","Development of FAPI PET as a Non-invasive Biomarker of Pulmonary Fibrogenesis","Inclusion Criteria:\n\n* Age 18 years or older\n* Able and willing to provide informed consent\n* Group A: Clinically evaluated for need for initiation of new treatment (in patients not on current treatment), initiation of change in current treatment, or addition of new treatment (to any current treatment) in the setting of fibrotic hypersensitivity pneumonitis (HSP) or idiopathic pulmonary fibrosis (IPF), per standard of clinical care at UW Health.\n* Group B: Clinically evaluated and stable without need for initiation of new treatment (in patients not on current treatment), initiation of change in current treatment, nor addition of new treatment (to any current treatment) in the setting of fibrotic hypersensitivity pneu-monitis (HSP) or idiopathic pulmonary fibrosis (IPF), per standard of clinical care at UW Health.\n* Crossover (Group B to A): Enrolled in Group B and found at next SOC clinical follow up to have need for initiation of new treatment (in patients not on current treatment), initiation of change in current treatment, or addition of new treatment (to any current treatment) in the setting of fibrotic hypersensitivity pneumonitis (HSP) or idiopathic pulmonary fibrosis (IPF), per standard of clinical care at UW Health.\n* Willing and able to undergo PET\u002FMRI.\n* Participants requiring intravenous (IV) conscious sedation for imaging are not eligible; participants requiring mild, oral anxiolytics for the clinical MRI will be allowed to participate as long as the following criteria are met:\n\n  * The subject has their own prescription for the medication\n  * Informed consent is obtained prior to the self-administration of this medication\n  * They come to the research visit with a driver\n\nExclusion Criteria:\n\n* Participant is unable or unwilling to provide informed consent\n* Participant is pregnant\n* Participant with contraindication(s) to or inability to undergo PET\u002FMRI\n* Participants with contraindications to GBCA will be asked to undergo research imaging without the use of contrast. Contraindications may be severe kidney disease or previously documented GFR \\\u003C 30 ml\u002Fmin\u002F1.73 m2","ALL","18 Years",{"count":18,"type":19},50,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","The goal of this clinical trial is to gain more information about how fibroblast activation protein inhibitor (FAPI) binds to a certain type of cells in fibrotic lung tissue and how this information can be used to better diagnose and track fibrotic lung disease activity.\n\nParticipants will undergo up to 4 PET\u002FMRI scans using the FAPI radiotracer.",[25],"Fibrosis Lung",[27],"lung disease associated with fibrosis","RECRUITING","2026-03-09",{"date":31,"type":32},"2026-03-11","ACTUAL",{"date":34,"type":32},"2025-11-19",{"date":36,"type":19},"2027-09",{"name":38,"class":39},"University of Wisconsin, Madison","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":50,"targetDuration":52,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":40},"100619471","western-sweden-systemic-sclerosis-project-100619471","NCT07345052","Western Sweden Systemic Sclerosis Project","Western Sweden Systemic Sclerosis Project - A Study on Underlying Mechanisms for Disease Development and Predictors of Disease Activity and Treatment Response in Patients With Systemic Sclerosis","WESST","Inclusion Criteria:\n\n* Participants diagnosed with SSc according to the ACR and EULAR classification criteria\n\nExclusion Criteria:\n\n* Diagnosis of Mixed connective tissue disease\n* Not speaking or reading Swedish\n* With severe cognitive impairment\n* With blood count below specified limits\n* Allergy to local anaesthetic (for subjects who will provide a skin biopsy)",true,{"count":51,"type":19},150,"5 Years","OBSERVATIONAL","The main aim of the project is to identify key-factors involved in the development and progression of Systemic Sclerosis (SSc), a chronic invalidating rheumatic disease characterized by high mortality and insufficient treatment options. A cohort of patients with SSc will be collected at the Sahlgrenska University Hospital in Gothenburg, Skaraborg Hospital in Skövde, and Södra Älvsborg Hospital in Borås (Sweden). Thanks to a holistic approach including integrated analysis of blood, and skin samples as well as DNA, and with the use of state-of-the-art methods, this project aims to identify factors (e.g. genes, proteins, metabolites, and immune cell types) associated with the development of SSc and with the progression to a more aggressive phenotype. Functional studies using in vitro model systems and patient specimens will be also implemented. The findings of the current project could lead to the identification of possible diagnostic and prognostic markers for the disease as well as potential drug targets. This cohort will be also linked to the European Scleroderma Trial and Research (EUSTAR), which is an international SSc research network aiming to coordinate research activities on SSc from groups all over Europe in order to improve treatment, quality of life and mortality of patients with SSc.",[56,57,25,58],"Scleroderma, Systemic","Fibrosis; Skin","Interstitial Lung Disease Due to Systemic Disease","2026-01-07",{"date":61,"type":32},"2026-01-15",{"date":63,"type":32},"2022-06-20",{"date":65,"type":19},"2030-12-31",{"name":67,"class":39},"Sahlgrenska University Hospital",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":77,"conditions":78,"keywords":83,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":40},"100491656","practice-of-oxygenation-and-respiratory-support-during-fiberoptic-bronchoscopy-100491656","NCT05681962","Practice of Oxygenation and Respiratory Support During Fiberoptic Bronchoscopy","Practice of Oxygenation and Respiratory Support During Fiberoptic Bronchoscopy: the Oxy-FOB STUDY","Inclusion Criteria:\n\n* Need for any procedure with flexible FOB\n* Either outpatients in dedicated ambulatories, and admitted to any hospital ward or Intensive Care Unit (ICU)\n\nExclusion Criteria:\n\n* None",{"count":76,"type":19},10000,"The current practice of oxygenation and\u002For ventilation supports in patients undergoing Fiberoptic Bronchoscopy is very heterogeneous among studies published in the literature; in addition, clear outcomes advantages of one strategy over another currently lack.\n\nThe goal of this observational study is to describe the current practice of oxygenation and\u002For ventilation supports in patients undergoing Fiberoptic Bronchoscopy (FOB), stratified by baseline respiratory condition, co-morbidities, type of procedure and hospital settings.\n\nInvestigators will enroll all adult patients undergoing any fiberoptic bronchoscopy in any clinical settings (from outpatients to critically ill patients). No specific exclusion criteria are indicated for enrollment in this study.\n\nInvestigators will record the following data:\n\n* Patient's baseline data.\n* Type of FOB procedure: toilet bronchoscopy (for secretions, blood, mucus plugs removal), broncho-aspirate (BAS), bronchoalveolar lavage (BAL), brushing for cytology, biopsy, endobronchial ultrasound (EBUS). The type and size of bronchoscope (with or without an internal\u002Fexternal camera) and the time of the procedure will be also recorded.\n* Type of supportive strategy: no support, Standard Oxygen Therapy, High Flow Nasal Cannula, Continuous Positive Airway Pressure and or non invasive ventilation trough mask or helmet, invasive mechanical ventilation.\n* Sedation\n* Intra-procedural vital parameters\n* Occurrence of adverse events: desaturation (i.e. SpO2\\\u003C 90% for at least 10 seconds), severe desaturation (i.e. SpO2\\\u003C 80%), need for procedure interruption, hypotensive (systolic blood pressure \\\u003C90 mmHg) or hypertensive (systolic blood pressure \\>140 mmHg) events, new onset of cardiac arrhythmias (specify the rhythm) or myocardial ischemia or electrocardiographic ST-alterations, neurological events (i.e. severe sensorium depression, psychomotor agitation).\n* Post-procedural vital parameters (15 minutes after the procedure).\n* Clinical outcomes: need for support escalation, need for admission to ward (for outpatient) or ICU (for outpatients and ward-admitted patient).",[79,80,81,25,82],"Acute Respiratory Failure","Pneumonia","Lung Cancer","Interstitial Lung Disease",[84],"Bronchoscopy","2024-12-24",{"date":87,"type":32},"2024-12-30",{"date":89,"type":32},"2023-02-15",{"date":91,"type":19},"2026-01-31",{"name":93,"class":39},"University Magna Graecia",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":40},"100548067","fibrotic-interstitial-lung-disease-with-nocturnal-hypoxaemia-and-exercise-induced-desaturation-100548067","NCT06416163","FIBRotic Interstitial Lung Disease With Nocturnal hypOXaemia and EXercise Induced desaTuRAtion","A Prospective Observational Study Investigating Whether Nocturnal Hypoxaemia and Exercise Induced Desaturation Predict Functional Deterioration in Patients With Fibrotic Interstitial Lung Disease","FIBRINOX-EXTRA","Inclusion Criteria:\n\n1. Patients aged 18 year and over\n2. Tertiary MDT diagnosis of FILD with \\>10% fibrosis on CT chest as determined by the investigator. Underlying diagnoses to include but not limited to: idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonitis (NSIP), chronic hypersensitivity pneumonitis (CHP), connective tissue disease-related interstitial lung disease (CTD-ILD), fibrotic organising pneumonia (FOP) and pulmonary sarcoidosis.\n3. Able to provide informed written consent\n\nExclusion Criteria:\n\n1. The use of or any indication for long-term oxygen therapy (LTOT)\n2. Known moderate or severe obstructive sleep apnoea with an apnoea\u002Fhypopnoea index (AHI) or oxygen desaturation index (ODI) over 15 events per hour\n3. Radiological predominance of emphysema compared with fibrosis on CT chest\n4. Inability to complete all health status questionnaires as set out in this protocol, with appropriate support\n5. A confirmed diagnosis of pulmonary hypertension\n6. Significant cardiovascular comorbidity including severe, uncontrolled hypertension, uncontrolled arrhythmia, recent acute coronary syndrome within 30 days prior to study enrolment, that could mean exercise testing poses a risk to patient health, in the opinion of the investigator\n7. Musculoskeletal comorbidity that will preclude the participant's ability to reliably complete the complete 6-minute walk test (6MWT)\n8. Participation in another research project which may confound this study's research findings",{"count":103,"type":19},160,"This is an observational clinical research study investigating patients with fibrotic interstitial lung disease (fILD), also known as pulmonary fibrosis.\n\nIt is not known why some patients with fILD clinically deteriorate. This study will investigate whether measuring oxygen levels during sleep or exercise can help identify patients who are at increased risk of clinical deterioration.",[82,25,106],"Pulmonary Hypertension","NOT_YET_RECRUITING","2024-07-05",{"date":110,"type":32},"2024-07-08",{"date":112,"type":19},"2024-07-01",{"date":114,"type":19},"2029-07-01",{"name":116,"class":39},"Guy's and St Thomas' NHS Foundation Trust"]